These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 19459841)

  • 1. A parametric ROC model-based approach for evaluating the predictiveness of continuous markers in case-control studies.
    Huang Y; Pepe MS
    Biometrics; 2009 Dec; 65(4):1133-44. PubMed ID: 19459841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the predictiveness of a continuous marker.
    Huang Y; Sullivan Pepe M; Feng Z
    Biometrics; 2007 Dec; 63(4):1181-8. PubMed ID: 17489968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating prognostic accuracy of biomarkers under competing risk.
    Zheng Y; Cai T; Jin Y; Feng Z
    Biometrics; 2012 Jun; 68(2):388-96. PubMed ID: 22150576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing risk prediction models in case-control studies using semiparametric and nonparametric methods.
    Huang Y; Pepe MS
    Stat Med; 2010 Jun; 29(13):1391-410. PubMed ID: 20527013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying combinations of cancer markers for further study as triggers of early intervention.
    Baker SG
    Biometrics; 2000 Dec; 56(4):1082-7. PubMed ID: 11129464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
    Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
    Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Semiparametric methods for evaluating the covariate-specific predictiveness of continuous markers in matched case-control studies.
    Huang Y; Pepe MS
    J R Stat Soc Ser C Appl Stat; 2010; 59(3):437-456. PubMed ID: 21562626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis.
    Louie KS; Seigneurin A; Cathcart P; Sasieni P
    Ann Oncol; 2015 May; 26(5):848-864. PubMed ID: 25403590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating the predictiveness of a marker with its performance as a classifier.
    Pepe MS; Feng Z; Huang Y; Longton G; Prentice R; Thompson IM; Zheng Y
    Am J Epidemiol; 2008 Feb; 167(3):362-8. PubMed ID: 17982157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bayesian semiparametric estimation of covariate-dependent ROC curves.
    Rodríguez A; Martínez JC
    Biostatistics; 2014 Apr; 15(2):353-69. PubMed ID: 24174579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of gamma-seminoprotein in combination with prostate specific antigen in detecting prostate cancer.
    Nakashima J; Nagata H; Sumitomo M; Miyajima A; Tachibana M; Baba S; Jitsukawa S; Murai M
    Int J Urol; 1999 Jun; 6(6):298-304. PubMed ID: 10404306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The residual-based predictiveness curve: A visual tool to assess the performance of prediction models.
    Casalicchio G; Bischl B; Boulesteix AL; Schmid M
    Biometrics; 2016 Jun; 72(2):392-401. PubMed ID: 26676377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study.
    Lin DW; Newcomb LF; Brown MD; Sjoberg DD; Dong Y; Brooks JD; Carroll PR; Cooperberg M; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Zheng Y;
    Eur Urol; 2017 Sep; 72(3):448-454. PubMed ID: 27889277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving prostate cancer detection in veterans through the development of a clinical decision rule for prostate biopsy.
    Hill OT; Mason TJ; Schwartz SW; Foulis PR
    BMC Urol; 2013 Jan; 13():6. PubMed ID: 23356551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incorporating the time dimension in receiver operating characteristic curves: a case study of prostate cancer.
    Etzioni R; Pepe M; Longton G; Hu C; Goodman G
    Med Decis Making; 1999; 19(3):242-51. PubMed ID: 10424831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel model to predict positive prostate biopsy based on serum androgen level.
    Ujike T; Uemura M; Kawashima A; Nagahara A; Fujita K; Miyagawa Y; Nonomura N
    Endocr Relat Cancer; 2018 Jan; 25(1):59-67. PubMed ID: 29046289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients.
    Lorente JA; Valenzuela H; Morote J; Gelabert A
    Eur J Nucl Med; 1999 Jun; 26(6):625-32. PubMed ID: 10369948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining biomarkers to detect disease with application to prostate cancer.
    Etzioni R; Kooperberg C; Pepe M; Smith R; Gann PH
    Biostatistics; 2003 Oct; 4(4):523-38. PubMed ID: 14557109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining 33 genetic variants with prostate-specific antigen for prediction of prostate cancer: longitudinal study.
    Johansson M; Holmström B; Hinchliffe SR; Bergh A; Stenman UH; Hallmans G; Wiklund F; Stattin P
    Int J Cancer; 2012 Jan; 130(1):129-37. PubMed ID: 21328341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.